Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.

Autor:	Tentori CA; Humanitas Clinical and Research Center-IRCCS & Department of Biomedical Sciences Humanitas University Milan Italy.; Comprehensive Cancer Centre, King's College London UK., Zhao LP; Hématologie seniors Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP) Paris France.; INSERM UMR_S1160, Institut de Recherche Saint Louis Université Paris Cité Paris France., Tinterri B; Humanitas Clinical and Research Center-IRCCS & Department of Biomedical Sciences Humanitas University Milan Italy., Strange KE; Comprehensive Cancer Centre, King's College London UK.; Research Group of Molecular Immunology Francis Crick Institute London UK., Zoldan K; Department of Medicine 1, Haematology, Cellular Therapy, Hemostaseology and Infectious Diseases University Medical Center Leipzig Leipzig Germany., Dimopoulos K; Department of Clinical Biochemistry Bispebjerg and Frederiksberg Hospital Copenhagen Denmark.; Department of Pathology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark., Feng X; Hematology Branch, National Heart, Lung and Blood Institute Bethesda Maryland USA., Riva E; Humanitas Clinical and Research Center-IRCCS & Department of Biomedical Sciences Humanitas University Milan Italy., Lim B; Imperial College London London UK., Simoni Y; Université Paris Cité, CNRS, INSERM, Institut Cochin Paris France., Murthy V; Centre for Clinical Haematology, University Hospitals of Birmingham Birmingham UK., Hayes MJ; Cell & Developmental Biology Vanderbilt University School of Medicine Nashville Tennessee USA.; Pathology, Microbiology and Immunology, Vanderbilt University Medical Center Nashville Tennessee USA.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center Nashville Tennessee USA., Poloni A; Department of Clinical and Molecular Sciences Università Politecnica delle Marche Ancona Italy., Padron E; Moffitt Cancer Center, Malignant Hematology Department Tampa USA., Cardoso BA; Universidade Católica Portuguesa Faculdade de Medicina Portugal.; Universidade Católica Portuguesa, Centro de Investigação Interdisciplinar em Saúde Portugal., Cross M; Department of Medicine 1, Haematology, Cellular Therapy, Hemostaseology and Infectious Diseases University Medical Center Leipzig Leipzig Germany., Winter S; Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden Dresden Germany., Santaolalla A; Comprehensive Cancer Centre, King's College London UK., Patel BA; Hematology Branch, National Heart, Lung and Blood Institute Bethesda Maryland USA., Groarke EM; Hematology Branch, National Heart, Lung and Blood Institute Bethesda Maryland USA., Wiseman DH; Division of Cancer Sciences The University of Manchester Manchester UK.; The Christie NHS Foundation Trust Manchester UK., Jones K; Immunophenotyping Laboratory (Synnovis Analytics LLP) Southeast Haematological Malignancy Diagnostic Service, King's College Hospital London UK., Jamieson L; Immunophenotyping Laboratory (Synnovis Analytics LLP) Southeast Haematological Malignancy Diagnostic Service, King's College Hospital London UK., Manogaran C; Immunophenotyping Laboratory (Synnovis Analytics LLP) Southeast Haematological Malignancy Diagnostic Service, King's College Hospital London UK., Daver N; University of Texas MD Anderson Cancer Center Houston, Texas USA., Gallur L; Hematology Department, Vall d'hebron University Hospital, Vall d'hebron Institut of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain., Ingram W; Department of Haematology University Hospital of Wales Cardiff UK., Ferrell PB; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center Nashville Tennessee USA.; Vanderbilt University Medical Center Nashville Tennessee USA., Sockel K; Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden Dresden Germany., Dulphy N; INSERM UMR_S1160, Institut de Recherche Saint Louis Université Paris Cité Paris France.; Laboratoire d'Immunologie et d'Histocompatibilité, Assistance Publique des Hôpitaux de Paris (APHP), Hôpital Saint-Louis Paris France.; Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis Paris France., Chapuis N; Université Paris Cité, CNRS, INSERM, Institut Cochin Paris France.; Assistance Publique-Hôpitaux de Paris Centre, Hôpital Cochin Paris France., Kubasch AS; Department of Medicine 1, Haematology, Cellular Therapy, Hemostaseology and Infectious Diseases University Medical Center Leipzig Leipzig Germany., Olsnes AM; Section for Hematology, Department of Medicine Haukeland University Hospital Bergen Norway.; Department of Clinical Science Faculty of Medicine, University of Bergen Bergen Norway., Kulasekararaj A; Department of Haematology King's College Hospital, Denmark Hill London UK., De Lavellade H; Haematology Department Guy's and St Thomas NHS Trust London UK., Kern W; MLL Münchner Leukämielabor Munich Germany., Van Hemelrijck M; Comprehensive Cancer Centre, King's College London UK., Bonnet D; Hematopoietic Stem Cell Laboratory Francis Crick Institute London UK., Westers TM; Department of Hematology, Cancer Center Amsterdam Amsterdam University Medical Centers, location VU University Medical Center Amsterdam The Netherlands., Freeman S; Institute of Immunology and Immunotherapy University of Birmingham Birmingham UK., Oelschlaegel U; Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden Dresden Germany., Valcarcel D; Hematology Department, Vall d'hebron University Hospital, Vall d'hebron Institut of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain., Raddi MG; Myelodysplastic Syndrome Unit, Hematology Division Azienda Ospedaliero-Universitaria Careggi, University of Florence Florence Italy., Grønbæk K; Department of Hematology, Rigshospitalet Copenhagen University Hospital Copenhagen Denmark.; Biotech Research and Innovation Center (BRIC) University of Copenhagen Copenhagen Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark., Fontenay M; Université Paris Cité, CNRS, INSERM, Institut Cochin Paris France.; Assistance Publique-Hôpitaux de Paris Centre, Hôpital Cochin Paris France., Loghavi S; University of Texas MD Anderson Cancer Center Houston, Texas USA., Santini V; Myelodysplastic Syndrome Unit, Hematology Division Azienda Ospedaliero-Universitaria Careggi, University of Florence Florence Italy., Almeida AM; Hematology Department Hospital da Luz Lisboa Lisboa Portugal.; Deanery Faculdade de Medicina, UCP Lisboa Portugal., Irish JM; Cell & Developmental Biology Vanderbilt University School of Medicine Nashville Tennessee USA.; Pathology, Microbiology and Immunology, Vanderbilt University Medical Center Nashville Tennessee USA.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center Nashville Tennessee USA., Sallman DA; Moffitt Cancer Center, Malignant Hematology Department Tampa USA., Young NS; Hematology Branch, National Heart, Lung and Blood Institute Bethesda Maryland USA., van de Loosdrecht AA; Department of Hematology, Cancer Center Amsterdam Amsterdam University Medical Centers, location VU University Medical Center Amsterdam The Netherlands., Adès L; Hématologie seniors Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP) Paris France.; Université Paris Cité, CNRS, INSERM, Institut Cochin Paris France., Della Porta MG; Humanitas Clinical and Research Center-IRCCS & Department of Biomedical Sciences Humanitas University Milan Italy., Cargo C; Leeds Teaching Hospital Leeds UK., Platzbecker U; Department of Medicine 1, Haematology, Cellular Therapy, Hemostaseology and Infectious Diseases University Medical Center Leipzig Leipzig Germany., Kordasti S; Comprehensive Cancer Centre, King's College London UK.; Department of Clinical and Molecular Sciences Università Politecnica delle Marche Ancona Italy.; Haematology Department Guy's and St Thomas NHS Trust London UK.
Jazyk:	angličtina
Zdroj:	HemaSphere [Hemasphere] 2024 May 15; Vol. 8 (5), pp. e64. Date of Electronic Publication: 2024 May 15 (Print Publication: 2024).
DOI:	10.1002/hem3.64
Abstrakt:	Advancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models have substantively advanced risk stratification, recent revelations have emphasized the pivotal role of immune dysregulation within the bone marrow milieu during MDS evolution. Nonetheless, immunotherapy for MDS has not experienced breakthroughs seen in other malignancies, partly attributable to the absence of an immune classification that could stratify patients toward optimally targeted immunotherapeutic approaches. A pivotal obstacle to establishing "immune classes" among MDS patients is the absence of validated accepted immune panels suitable for routine application in clinical laboratories. In response, we formed International Integrative Innovative Immunology for MDS (i4MDS), a consortium of multidisciplinary experts, and created the following recommendations for standardized methodologies to monitor immune responses in MDS. A central goal of i4MDS is the development of an immune score that could be incorporated into current clinical risk stratification models. This position paper first consolidates current knowledge on MDS immunology. Subsequently, in collaboration with clinical and laboratory specialists, we introduce flow cytometry panels and cytokine assays, meticulously devised for clinical laboratories, aiming to monitor the immune status of MDS patients, evaluating both immune fitness and identifying potential immune "risk factors." By amalgamating this immunological characterization data and molecular data, we aim to enhance patient stratification, identify predictive markers for treatment responsiveness, and accelerate the development of systems immunology tools and innovative immunotherapies. Competing Interests: Shahram Kordasti: Novartis: Advisory Board, Speakers bureau, Alexion: Speakers bureau, Beckman Coulter: Speakers bureau, MorphoSys: Research Support (none is related to this publication). Wolfgang Kern declares part‐ownership of MLL Munich Leukemia Laboratory. Austin Kulasekararaj: Research support (to institution): Celgene/BMS and Novartis. Speaker's fees: Alexion/AstraZeneca, Akari, Apellis, Celgene/BMS, Novartis, Pfizer, Ra Pharma/UCB, Roche, SOBI. Scientific advisory board: Alexion/Astra Zeneca, Apellis, Amgen, Agios, Biocryst, Celgene/BMS, Novartis, Pfizer, Regeneron, Roche, SOBI, Janssen, Samsung and Novo Nordisk (none is related to this publication). (© 2024 The Authors. HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematology Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text